Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Steff

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Molecular Biology Reports|March 1, 1997
Complex mechanisms for c-fos and c-jun degradationI Jariel-Encontre, C Salvat, A M Steff, et al.
La Revue De Medecine Interne|November 26, 2008
[Cutaneous EBV-associated lymphoproliferative disorder in a dermatomyositis treated with immunosuppressive agents]M Steff, Y Le Corre, I Penisson-Besnier, et al.
Molecular Biology Reports|June 11, 1999
Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?C Salvat, C Aquaviva, I Jariel-Encontre, et al.
Annales De Dermatologie Et De Venereologie|March 16, 2010
[Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]M Steff, A Bourillon, T Frebourg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2019
Tattoo complications in treated and non-treated psoriatic patientsC Grodner, A Beauchet, A-C Fougerousse, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2019
Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical settingA-C Fougerousse, F Maccari, A Beauchet, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 24, 2022
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)J Zitouni, A-C Bursztejn, A Belloni Fortina, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Molecular Biology Reports|March 1, 1997
Complex mechanisms for c-fos and c-jun degradationI Jariel-Encontre, C Salvat, A M Steff, et al.
La Revue De Medecine Interne|November 26, 2008
[Cutaneous EBV-associated lymphoproliferative disorder in a dermatomyositis treated with immunosuppressive agents]M Steff, Y Le Corre, I Penisson-Besnier, et al.
Molecular Biology Reports|June 11, 1999
Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?C Salvat, C Aquaviva, I Jariel-Encontre, et al.
Annales De Dermatologie Et De Venereologie|March 16, 2010
[Intra- and interfamilial phenotype variation in Birt-Hogg-Dubé syndrome: Consequences for therapy]M Steff, A Bourillon, T Frebourg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2019
Tattoo complications in treated and non-treated psoriatic patientsC Grodner, A Beauchet, A-C Fougerousse, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2019
Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical settingA-C Fougerousse, F Maccari, A Beauchet, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 24, 2022
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)J Zitouni, A-C Bursztejn, A Belloni Fortina, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 3